Literature DB >> 26646849

Low intratumoral regulatory T cells and high peritumoral CD8(+) T cells relate to long-term survival in patients with pancreatic ductal adenocarcinoma after pancreatectomy.

Li Liu1, Guochao Zhao1, Wenchuan Wu2, Yefei Rong1, Dayong Jin1, Dansong Wang1, Wenhui Lou3, Xinyu Qin1.   

Abstract

The prognosis for pancreatic ductal adenocarcinoma (PDAC) remains extremely poor. Recent studies have focused on the role of lymphocytes in the PDAC microenvironment. Using immunohistochemistry, our study explored the clinical significance of intratumoral or peritumoral CD4(+)Foxp3(+) regulatory T cells (Tregs) and CD8(+) T cells in the tumor microenvironment and analyzed their relation to the prognosis of PDAC in a consecutive series of 92 patients after resection. CD8(+) T cells were more frequently seen within peritumoral sites, while CD4(+)Foxp3(+) Tregs were more frequent within intratumoral areas. Neither exhibited any relationship with other clinicopathologic factors. Patients with low levels of intratumoral Tregs had longer disease-free survival than those with higher levels (DFS 22.2 vs. 11.2 months, p < 0.001), and patients with higher levels of peritumoral CD8(+) T cells had longer overall survival than those with lower levels (OS 31.0 vs. 14.2 months, p < 0.001). Multivariate analysis demonstrated that intratumoral Tregs (hazard ratio, HR 3.39, p = 0.010) and peritumoral CD8(+) T cells (HR 0.10, p < 0.001) are related to DFS and OS, respectively. These results indicate that intratumoral Tregs are a negative predictor of DFS, while peritumoral CD8(+) T cells are a positive predictor of OS for PDAC patients with pancreatectomy.

Entities:  

Keywords:  CD8+ T cells; Pancreatectomy; Pancreatic ductal adenocarcinoma; Prognosis; Tregs; Tumor microenvironment

Mesh:

Year:  2015        PMID: 26646849     DOI: 10.1007/s00262-015-1775-4

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  27 in total

1.  Comparative bioinformatical analysis of pancreatic head cancer and pancreatic body/tail cancer.

Authors:  Lingdi Yin; Linmei Xiao; Yong Gao; Guangfu Wang; Hao Gao; Yunpeng Peng; Xiaole Zhu; Jishu Wei; Yi Miao; Kuirong Jiang; Zipeng Lu
Journal:  Med Oncol       Date:  2020-04-10       Impact factor: 3.064

2.  Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer.

Authors:  Yingjie Nie; Jiang He; Hidekazu Shirota; Anna L Trivett; Dennis M Klinman; Joost J Oppenheim; Xin Chen
Journal:  Sci Signal       Date:  2018-01-02       Impact factor: 8.192

3.  Methyl-indole inhibits pancreatic cancer cell viability by down-regulating ZFX expression.

Authors:  Xueliang Qin; Xiaopeng Cui
Journal:  3 Biotech       Date:  2020-03-31       Impact factor: 2.406

Review 4.  Strategies for Increasing Pancreatic Tumor Immunogenicity.

Authors:  Burles A Johnson; Mark Yarchoan; Valerie Lee; Daniel A Laheru; Elizabeth M Jaffee
Journal:  Clin Cancer Res       Date:  2017-04-01       Impact factor: 12.531

5.  The Crosstalk Between Immune Infiltration, Circulating Tumor Cells, and Metastasis in Pancreatic Cancer: Identification of HMGB3 From a Multiple Omics Analysis.

Authors:  Hao-Dong Tang; Yang Wang; Peng Xie; Si-Yuan Tan; Hai-Feng Li; Hao Shen; Zheng Zhang; Zheng-Qing Lei; Jia-Hua Zhou
Journal:  Front Genet       Date:  2022-06-08       Impact factor: 4.772

6.  Outcome of head compared to body and tail pancreatic cancer: a systematic review and meta-analysis of 93 studies.

Authors:  Gianluca Tomasello; Michele Ghidini; Antonio Costanzo; Antonio Ghidini; Alessandro Russo; Sandro Barni; Rodolfo Passalacqua; Fausto Petrelli
Journal:  J Gastrointest Oncol       Date:  2019-04

7.  Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma.

Authors:  Robyn D Gartrell; Thomas Enzler; Pan S Kim; Benjamin T Fullerton; Ladan Fazlollahi; Andrew X Chen; Hanna E Minns; Subha Perni; Stuart P Weisberg; Emanuelle M Rizk; Samuel Wang; Eun Jeong Oh; Xinzheng V Guo; Codruta Chiuzan; Gulam A Manji; Susan E Bates; John Chabot; Beth Schrope; Michael Kluger; Jean Emond; Raul Rabadán; Donna Farber; Helen E Remotti; David P Horowitz; Yvonne M Saenger
Journal:  Oncoimmunology       Date:  2022-05-05       Impact factor: 7.723

8.  Prognostic significance of tumor infiltrating immune cells in oral squamous cell carcinoma.

Authors:  Juan Fang; Xiaoxu Li; Da Ma; Xiangqi Liu; Yichen Chen; Yun Wang; Vivian Wai Yan Lui; Juan Xia; Bin Cheng; Zhi Wang
Journal:  BMC Cancer       Date:  2017-05-26       Impact factor: 4.430

9.  Glycolysis-Related Gene Expression Profiling Screen for Prognostic Risk Signature of Pancreatic Ductal Adenocarcinoma.

Authors:  Wenjing Song; Xin He; Pengju Gong; Yan Yang; Sirui Huang; Yifan Zeng; Lei Wei; Jingwei Zhang
Journal:  Front Genet       Date:  2021-06-23       Impact factor: 4.599

10.  Genome-scale analysis to identify prognostic markers in patients with early-stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy.

Authors:  Xiwen Liao; Ketuan Huang; Rui Huang; Xiaoguang Liu; Chuangye Han; Long Yu; Tingdong Yu; Chengkun Yang; Xiangkun Wang; Tao Peng
Journal:  Onco Targets Ther       Date:  2017-09-12       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.